Developed and managed Intellectual Property portfolio for Constellation Pharmaceuticals, Inc., (NASDAQ: CNST) and participated in the diligence and strategic efforts leading to the acquisition agreement with MorphoSys AG (FSE: MOR; NASDAQ: MOR) (“MorphoSys”). The 1.7 billion dollar deal is funded by a second deal between MorphoSys (ticker: MOR) and Royalty Pharma (RPRX), which specializes in acquiring royalty rights from drug companies. Constellation’s two lead product candidates, pelabresib (CPI-0610), a BET inhibitor, and CPI-0209, a second-generation EZH2 inhibitor, are in mid- to late-stage clinical trials, and have broad therapeutic potential to offer meaningful benefits to patients with various hematological and solid tumors.
McCarter & English, LLP | Contents of this website may contain attorney advertising. | Results may vary depending on your particular facts and legal circumstances.